Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Key Points
Acuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares.
At the end of the first quarter the firm held 592,108 shares held, valued at $5 million.
The position now represents 3.5% of the fund's AUM.
- 10 stocks we like better than Ocular Therapeutix ›
According to the SEC filing dated May 15, Acuta Capital Partners, LLC disclosed a first-quarter sale of 460,887 shares of Ocular Therapeutix (NASDAQ:OCUL).
- Reduced Ocular Therapeutix holdings by 460,887 shares
- Post-trade: 592,108 shares held, valued at $5. million as of March 31, 2026
- The position now represents 3.5% of the fund’s AUM
What else to know
- Top holdings after the filing:
- NASDAQ:PRAX: $27.4 million (19.3% of AUM)
- NASDAQ:TERN (subsequently acquired): $26.1 million (18.4% of AUM)
- NASDAQ:WHWK: $11.8 million (8.3% of AUM)
- NASDAQ:TNGX: $9.2 million (6.5% of AUM)
- NASDAQ:DRUG: $8.2 million (5.8% of AUM)
Company Overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $52.0 million |
| Net Income (TTM) | ($290.5 million) |
| Price (as of market close May 26) | $8.29 |
Company Snapshot
Ocular Therapeutix is a biopharmaceutical company specializing in therapies for eye diseases and leveraging its bioresorbable hydrogel-based formulation technology. The company seeks to actively develop new treatments and form strategic partnerships to address unmet needs in ophthalmology.
- Ocular Therapeutix offers ophthalmic products such as ReSure Sealant and DEXTENZA, and is advancing a pipeline including OTX-TKI, OTX-TIC, OTX-CSI, and OTX-DED for a range of ocular diseases.
- The company generates revenue through sales of FDA-approved ophthalmic devices and drug inserts, with additional value driven by licensing and strategic collaborations for its proprietary sustained-release hydrogel technology.
- Primary customers include ophthalmologists, surgical centers, and healthcare providers treating patients with ocular inflammation, pain, glaucoma, and retinal diseases.
What this transaction means for investors
Investors should take note that Acuta Capital, an investment firm specializing in the healthcare sector, sold a significant number of Ocular Therapeutix shares. The holding, previously its fourth largest, accounted for 8.7% of its reported AUM as of Dec. 31.
The shares have lagged the overall equity market. Over the last year, through May 26, Ocular Therapeutix shares gained 12.7% compared to total returns of 30.4% for the S&P 500 index and 41.5% for the Nasdaq Composite.
An investment in Ocular Therapeutix stock isn’t for the faint of heart. The company generated only $10.8 million in first-quarter revenue, and it lost $88.6 million.
The company has been conducting trials for several products. If these prove successful, Ocular Therapeutix could see a major upswing in revenue. But it’s not certain that these treatments will receive governmental approval and penetrate the ocular market.
Interested investors should watch for upcoming news coming out of its investor day on June 17.
Should you buy stock in Ocular Therapeutix right now?
Before you buy stock in Ocular Therapeutix, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ocular Therapeutix wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 26, 2026.
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
